PE20030591A1 - Formulaciones de acitromicina directamente compresibles - Google Patents

Formulaciones de acitromicina directamente compresibles

Info

Publication number
PE20030591A1
PE20030591A1 PE2002001219A PE2002001219A PE20030591A1 PE 20030591 A1 PE20030591 A1 PE 20030591A1 PE 2002001219 A PE2002001219 A PE 2002001219A PE 2002001219 A PE2002001219 A PE 2002001219A PE 20030591 A1 PE20030591 A1 PE 20030591A1
Authority
PE
Peru
Prior art keywords
acitromycin
acithromycin
forms
mixture
solvate
Prior art date
Application number
PE2002001219A
Other languages
English (en)
Inventor
Steven William Collier
Ernest Shing Quan
Brendan Jhon Murphy
Barbara Alice Johnson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20030591A1 publication Critical patent/PE20030591A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA MEZCLA GENERALMENTE HOMOGENEA DE DOS O MAS MATERIALES EN FORMA DE PARTICULAS, PARA FORMAR COMPRIMIDOS DE ACITROMICINA POR COMPRESION DIRECTA, QUE COMPRENDE: a)ACITROMICINA NO DIHIDRATADA, NO GRANULADA, SELECCIONADA DE LAS FORMAS: B, D, E, F, ENTRE OTRAS ; Y, b)AL MENOS UN EXCIPIENTE FARMACEUTICAMENTE ACEPTABLE. DONDE, EL ANGULO INTERNO DE FRICCION DE LA MEZCLA ES MENOR DE APROXIMADAMENTE 34°; EL 14%, EN VOLUMEN DEL TOTAL DE PARTICULAS DE ACITROMICINA, TIENE UN DIAMETRO DE 44 µm O MENOS Y LAS FORMAS B Y F PERTENECEN A LA FAMILIA I DE ACITROMICINA Y A UN GRUPO ESPACIAL P21 MONOCLINICO CON DIMENSIONES DE CELDA DE a=16,3+/-0,3 Å, b=16,2+/-0,3 Å, c=18,4+/-0,3 Å Y ß=109+/-2° Y LAS FORMAS D Y E PERTENECEN A LA FAMILIA II DE LA ACITROMICINA AL GRUPO ESPACIAL P212121 ORTORROMBICO, CON DIMENSIONES DE CELDA A a=8,9+/-0,4 Å, b=12,3+/-0,5 Å, c=45,8+/-0,5 Å; SIENDO D UN SOLVATO MONOHIDRATADO DE MONOCICLOHEXANO Y ACITROMICINA Y E UN SOLVATO MONOHIDRATADO DE MONOTETRAHIDROFURANO Y ACITROMICINA. SE REFIERE TAMBIEN A UN PROCESO PARA PREPARAR DICHO COMPRIMIDO, QUE COMPRENDE: 1)FORMACION DE UNA MEZCLA EN SECO DE UNA FORMA A DE ACITROMICINA NO GRANULADA Y (b); Y, 2)COMPRESION DIRECTA DE DICHA MEZCLA EN SECO PARA FORMAR EL COMPRIMIDO
PE2002001219A 2001-12-21 2002-12-13 Formulaciones de acitromicina directamente compresibles PE20030591A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34348001P 2001-12-21 2001-12-21

Publications (1)

Publication Number Publication Date
PE20030591A1 true PE20030591A1 (es) 2003-07-12

Family

ID=23346277

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002001219A PE20030591A1 (es) 2001-12-21 2002-12-13 Formulaciones de acitromicina directamente compresibles

Country Status (20)

Country Link
US (4) US20030165563A1 (es)
EP (1) EP1455758A1 (es)
JP (1) JP2005513099A (es)
KR (1) KR100632339B1 (es)
CN (1) CN1668282A (es)
AR (1) AR037930A1 (es)
AU (1) AU2002348884A1 (es)
BR (1) BR0215193A (es)
CA (1) CA2469246A1 (es)
IL (1) IL161996A0 (es)
MX (1) MXPA04005105A (es)
NO (1) NO20043110L (es)
NZ (1) NZ532707A (es)
PA (1) PA8562201A1 (es)
PE (1) PE20030591A1 (es)
PL (1) PL371259A1 (es)
RU (1) RU2277914C2 (es)
TW (1) TW200301138A (es)
WO (1) WO2003053416A1 (es)
ZA (1) ZA200403486B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020231A2 (en) * 2002-03-18 2003-12-31 Pliva D D ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
MXPA04005105A (es) * 2001-12-21 2004-08-19 Pfizer Prod Inc Formulaciones de acitromicina directamente compresibles.
FR2834889B1 (fr) * 2002-01-18 2004-04-02 Roquette Freres Forme pharmaceutique solide orodispersible
GB0211620D0 (en) * 2002-05-21 2002-07-03 Bioprogress Technology Ltd Powder compaction and enrobing
US20030228370A1 (en) * 2002-06-11 2003-12-11 Michel Serpelloni Orodispersible solid pharmaceutical form
HRP20020614A2 (en) * 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
WO2005002592A2 (en) * 2003-07-01 2005-01-13 Ranbaxy Laboratories Limited Stable oral compositions of azithromycin monohydrate
WO2005004919A2 (en) * 2003-07-02 2005-01-20 Eurand, Inc. Extended release systems for macrolide antibiotics
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
US20050101547A1 (en) * 2003-11-06 2005-05-12 Sadatrezaei Mohsen Stabilized azithromycin composition
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
BRPI0416534A (pt) 2003-12-04 2007-01-09 Pfizer Prod Inc composições multiparticuladas com estabilidade melhorada
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
MXPA06005913A (es) * 2003-12-04 2006-06-27 Pfizer Prod Inc Formas de dosificacion de multiparticulas de azitromicina por procedimientos basados en liquidos.
BRPI0417348A (pt) * 2003-12-04 2007-03-13 Pfizer Prod Inc processo de gelatinização por spray com utilização de uma extrusora para preparação de composições de droga cristalina multiparticulada contendo preferencialmente um poloxámero e um glicerìdeo
PL1691787T3 (pl) 2003-12-04 2008-11-28 Pfizer Prod Inc Sposób wytwarzania farmaceutycznych systemów wielocząstkowych
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US20100048498A1 (en) * 2004-12-21 2010-02-25 Johnson Barbara A Stable non-dihydrate azithromycin oral suspensions
US7901710B2 (en) * 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
WO2008024044A1 (en) * 2006-08-21 2008-02-28 Astrazeneca Ab Compositions, suitable for oral administration, comprising a triazolo [4, 5] pyrimidin derivate
TWI482772B (zh) * 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
WO2008074144A1 (en) * 2006-12-20 2008-06-26 Genpharm Ulc A composition containing a bisphosphonic acid in combination with vitamin d
BRPI0815376A2 (pt) * 2007-07-31 2014-10-07 Cargill Inc Dextrose diretamente compresível
WO2009059605A1 (en) * 2007-11-08 2009-05-14 University Of Copenhagen Small scale solid state screening
HUE028690T2 (en) * 2008-03-18 2016-12-28 Dikovskiy Aleksander Vladimirovich Antibiotic and prebiotic pharmaceutical composition for antibacterial therapy to prevent and treat dysbiosis
PL2266582T3 (pl) * 2008-03-18 2015-10-30 Dikovskiy Aleksander Vladimirovich Mieszanka farmaceutyczna do zapobiegania dysbiozie związanej z enteralnym podawaniem antybiotyków
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
AR083417A1 (es) * 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
KR20150092385A (ko) 2014-02-03 2015-08-13 씨제이헬스케어 주식회사 솔리페나신을 포함하는 안정한 제제 및 이의 제조방법
US20150242978A1 (en) 2014-02-24 2015-08-27 Mindojo Ltd. Content development and moderation flow for e-learning datagraph structures
US20160145548A1 (en) * 2014-11-20 2016-05-26 The Procter & Gamble Company Cleaning composition refill for an automatic dishwasher dispensing device
CN105193753A (zh) * 2015-10-30 2015-12-30 成都通德药业有限公司 一种阿奇霉素分散片的制备方法
CN110633487B (zh) * 2019-07-03 2023-03-14 北京中医药大学 直接压片的片剂处方的设计方法
CN111467362B (zh) * 2020-05-09 2021-07-06 北京四环制药有限公司 一种阿奇霉素药用组合物及其制备方法和其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
MX12213A (es) * 1987-07-09 1993-05-01 Pfizer Metodo de preparacion de dihidrato de azitromicina cristalino
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
TW271400B (es) * 1992-07-30 1996-03-01 Pfizer
US5795871A (en) * 1994-04-26 1998-08-18 Nobuhiro Narita Pharmaceutical composition for treatment of non-small cell lung cancer
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
RU2130311C1 (ru) * 1994-05-06 1999-05-20 Пфайзер Инк. Лекарственные формы азитромицина с контролируемым высвобождением
IL119866A (en) 1996-12-19 1999-12-31 Unipharm Ltd Antibiotic tablet
CO4920215A1 (es) 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
US6339063B1 (en) * 1997-09-10 2002-01-15 Merck & Co., Inc. 9a-azalides as veterinary antimicrobial agents
AU731842B2 (en) * 1997-09-10 2001-04-05 Merck & Co., Inc. 9a-azalides as veterinary antimicrobial agents
CA2245398C (en) * 1998-08-21 2002-01-29 Apotex Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
KR100603226B1 (ko) * 1998-11-30 2006-08-28 테바 파마슈티컬 인더스트리즈 리미티드 아지스로마이신의 에탄올레이트, 이의 제조 방법 및 약학 조성물
FR2793690B1 (fr) * 1999-03-30 2003-01-03 Cll Pharma Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique
ES2177373B1 (es) 1999-11-26 2003-11-01 Astur Pharma Sa Preparacion de azitromicina en su forma no cristalina
WO2002009640A2 (en) 2000-08-01 2002-02-07 Shiva Prasad Singh Process for the preparation of anhydrous azithromycin
US6861413B2 (en) * 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
AP2003002906A0 (en) * 2001-05-22 2003-12-31 Pfizer Prod Inc Crystal forms of azithromycin
DE60232005D1 (de) * 2001-10-18 2009-05-28 Teva Pharma Stabilisierte azithromycin-zusammensetzungen
MXPA04005105A (es) * 2001-12-21 2004-08-19 Pfizer Prod Inc Formulaciones de acitromicina directamente compresibles.
RU2283651C2 (ru) * 2001-12-21 2006-09-20 Пфайзер Продактс Инк. Способы мокрой грануляции азитромицина
PL372394A1 (en) * 2002-02-01 2005-07-25 Pfizer Products Inc. Dry granulated formulations of azithromycin

Also Published As

Publication number Publication date
NZ532707A (en) 2006-07-28
US20030165563A1 (en) 2003-09-04
NO20043110L (no) 2004-07-20
AR037930A1 (es) 2004-12-22
PA8562201A1 (es) 2003-07-28
US20050287209A1 (en) 2005-12-29
AU2002348884A1 (en) 2003-07-09
RU2277914C2 (ru) 2006-06-20
IL161996A0 (en) 2005-11-20
MXPA04005105A (es) 2004-08-19
US20060024364A1 (en) 2006-02-02
CA2469246A1 (en) 2003-07-03
ZA200403486B (en) 2006-05-31
KR20040066175A (ko) 2004-07-23
RU2004118709A (ru) 2005-04-20
JP2005513099A (ja) 2005-05-12
BR0215193A (pt) 2004-11-16
KR100632339B1 (ko) 2006-10-12
US20060024363A1 (en) 2006-02-02
TW200301138A (en) 2003-07-01
WO2003053416A1 (en) 2003-07-03
US7070811B2 (en) 2006-07-04
EP1455758A1 (en) 2004-09-15
CN1668282A (zh) 2005-09-14
PL371259A1 (en) 2005-06-13

Similar Documents

Publication Publication Date Title
PE20030591A1 (es) Formulaciones de acitromicina directamente compresibles
Russo et al. Insect immunity: early events in the encapsulation process of parasitoid (Leptopilina boulardi) eggs in resistant and susceptible strains of Drosophila
CO5640076A2 (es) Composicion farmaceutica que comprende un inhibidor de ibat para el tratamiento o profilaxis del estreñimiento
AR077411A2 (es) Forma de dosificacion farmaceutica solida, con lopinavir y ritonavir, y proceso para su preparacion.
AR037695A1 (es) Composicion para el tratamiento del cabello
ES2522567T3 (es) Composición farmacéutica que comprende amlodipino y losartán
AR029825A1 (es) Una composicion farmaceuticamente aceptable que comprende carvedilol o una sal del mismo farmaceuticamente aceptable, un procedimiento para la produccion de dicha composicion y utilizacion de la misma
ECSP088379A (es) Tabletas dispersables que comprenden deferasirox
ATE493130T1 (de) Opioid enthaltende arzneiform gegen missbrauch
AR029605A1 (es) DERIVADOS DE DIFENILUREA SUBSTITUIDOS CON SULFONAMIDA , COMPOSICIoN FARMACEUTICA , USO DE LOS MISMOS PARA LA MANUFACTURA DE UN MEDICAMENTO uTILES COMO ANTAGONISTA DE RECEPTORES DE IL-8, COMPUESTOS, INTERMEDIARIOS, Y MÉTODOS DE CONVERSIoN DE COMPUESTOS
ES2147309T3 (es) Composiciones de ondansetron liofilizadas.
AR031547A1 (es) Forma fisica de la sustancia 5-cloro-n-[2-[4-[[[(ciclohexilamino)-carbonil]amino]sulfonil]fenil]etil]-2-metoxibenzamida (gliburida), el uso de dicha sustancia en una tableta o capsula, las tabletas o capsulas que la contienen y las tabletas o capsulas que la contienen asociada con un farmaco para el
UY25799A1 (es) Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina y otro agente antidiabético.
AP2002002426A0 (en) Ppar agonists
CO6321225A2 (es) Particulas portadoras sólidas para mejorar la procesabilidad de un agente farmacéutico
BR0316564A (pt) Forma de dosagem de alérgeno
GT200500036A (es) Desodorante seco contentivo de un alcohol de sesquiterpeno y oxido de zinc
PE68899A1 (es) Composicion que contiene paracetamol
AR031601A1 (es) Derivados de 4-pirimidinamina, composiciones farmaceuticas y metodos relacionados
AR050574A1 (es) Uso de un compuesto para estimulacion del crecimiento de pelo
CL2004001317A1 (es) Composicion farmaceutica que comprende el antagonista de receptores de progesterona 11b-(4-acetilfenil)-17b-hidroxi-17 alfa-(1,1,2,2,2-pentafluoroetil)-estra-4,9-dien-3-ona y un antiestrogeno puro; y su uso para tratar una enfermedad dependiente de h
AR062626A1 (es) Comprimidos de polimero de poliestireno sulfonato, su preparacion y uso
AR014881A1 (es) Uso de un sensibilizador a insulina y un agente antihiperglucemico para la preparacion de un medicamento y composicion farmaceutica que comprendedicho sensibilizador y dicho agente
MX9302985A (es) Composicion farmaceutica para el tratamiento y la profilaxis de la ansiedad.
PA8577801A1 (es) Polipeptido t1249 pegilado

Legal Events

Date Code Title Description
FD Application declared void or lapsed